Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 20/20 | 1.00 |
| ▸ | MMP13 | P45452 | 15/20 | 1.00 |
| ▸ | ADAM17 | P78536 | 12/20 | 1.00 |
| ▸ | MMP3 | P08254 | 10/20 | 1.00 |
| ▸ | MMP2 | P08253 | 10/20 | 1.00 |
| ▸ | MMP9 | P14780 | 10/20 | 1.00 |
| ▸ | MMP7 | P09237 | 8/20 | 1.00 |
| ▸ | MMP8 | P22894 | 6/20 | 1.00 |
| ▸ | MMP14 | P50281 | 2/20 | 1.00 |
| ▸ | ADAM10 | O14672 | 2/20 | 0.65 |
| ▸ | ADAM9 | Q13443 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prinomastat SCHEMBL3955053 | 1.00 | MMP1 (1.00) | MMP1MMP13ADAM17MMP3MMP2 | |
| Prinomastat SCHEMBL6801875 | 1.00 | MMP1 (1.00) | MMP1MMP13ADAM17MMP3MMP2 | |
| Prinomastat SCHEMBL7765017 | 0.99 | MMP1 (0.98) | MMP1MMP13ADAM17MMP3MMP2 | |
| Prinomastat SCHEMBL6810941 | 0.99 | MMP1 (0.98) | MMP1MMP13ADAM17MMP3MMP2 | |
| SCHEMBL12272301 | 0.92 | MMP1 (0.85) | MMP1MMP13ADAM17MMP3MMP2 | |
| SCHEMBL6432297 | 0.90 | MMP1 (0.81) | MMP1MMP13ADAM17MMP3MMP2 | |
| SCHEMBL6336108 | 0.90 | MMP1 (0.85) | MMP1MMP13ADAM17MMP3MMP2 | |
| SCHEMBL6432301 | 0.90 | MMP1 (0.81) | MMP1MMP13ADAM17MMP3MMP2 | |
| SCHEMBL3912779 | 0.90 | MMP1 (0.85) | MMP1MMP13ADAM17MMP3MMP2 | |
| SCHEMBL6344484 | 0.89 | MMP1 (0.83) | MMP1MMP13ADAM17MMP3MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9215 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139320-A1 | StarTrace: A Multiplex Drug Testing Platform for Personalized Medicine | UNIV OF SOUTH CAROLINA (US) | 2026-05-21 | — | — | US | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12564575-B2 | Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis | OPHIREX, INC (US) | 2026-03-03 | — | — | US | claimed |
| US-12548678-B2 | Methods and systems for machine learning analysis of single nucleotide polymorphisms in lupus | AMPEL BIOSOLUTIONS, LLC (US) | 2026-02-10 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20260007597-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRUS-INDUCED AIRWAY FIBROSIS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2026-01-08 | — | — | US | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | claimed |
| EP-4644418-A1 | NANOBODY TARGETING BCMA, CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | Hebei Senlang Biotechnology Co. Ltd. (CN) | 2025-11-05 | — | — | EP | claimed |
| US-12383531-B2 | PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury | OPHIREX, INC. (US) | 2025-08-12 | — | — | US | claimed |
| US-20250221991-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER METASTASES | UNIVERSITY OF CINCINNATI (US) | 2025-07-10 | — | — | US | claimed |
| US-20020147158-A1 | Composition and method for preventing and treating sinusoidal obstruction syndrome and radiation-induced liver disease | UNIVERSITY OF SOUTHERN CALIFORNIA | 2002-10-10 | — | — | US | claimed |
| WO-2002067870-A2 | COMPOSITION AND METHOD FOR PREVENTING AND TREATING SINUSOIDAL OBSTRUCTION SYNDROME AND RADIATION-INDUCED LIVER DISEASE | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2002-09-06 | — | — | WO | claimed |
| WO-2002059558-A2 | MEANS AND METHODS FOR TREATMENT EVALUATION | PRIMAGEN HOLDING B.V. (NL) | 2002-08-01 | — | — | WO | claimed |
| EP-1225233-A2 | Means and methods for treatment evaluation | Amsterdam Support Diagnostics B.V. (NL) | 2002-07-24 | — | — | EP | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| EP-0935963-A2 | The use of MMP-13 selective inhibitors for the treatment of osteoarthritis and other matrix metalloproteinase-mediated disorders | Pfizer Products Inc. (US) | 1999-08-18 | — | — | EP | claimed |
| EP-0874830-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES, AND METHODS AND INTERMEDIATES USEFUL FOR THEIR PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 1998-11-04 | — | — | EP | claimed |
| US-5753653-A | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses | AGOURON PHARMACEUTICALS, INC. (US) | 1998-05-19 | — | — | US | claimed |
| WO-1997020824-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES, AND METHODS AND INTERMEDIATES USEFUL FOR THEIR PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 1997-06-12 | — | — | WO | claimed |